Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MOXIFLOXACIN HYDROCHLORIDE IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER vs AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Inhibits DNA gyrase (topoisomerase II) and topoisomerase IV, thereby interfering with bacterial DNA replication, transcription, repair, and recombination.
Aminophylline is a complex of theophylline and ethylenediamine. Theophylline acts as a non-selective phosphodiesterase inhibitor, increasing intracellular cyclic AMP levels, leading to bronchodilation. It also blocks adenosine receptors, stimulates catecholamine release, and enhances diaphragmatic contractility. The ethylenediamine component increases solubility.
Community-acquired pneumonia,Acute bacterial sinusitis,Acute bacterial exacerbation of chronic bronchitis,Skin and skin structure infections (uncomplicated and complicated),Complicated intra-abdominal infections,Pelvic inflammatory disease,Urinary tract infections (complicated and uncomplicated),Prophylaxis of anthrax exposure,Plague,Empiric therapy in febrile neutropenia (off-label)
Treatment of symptoms and reversible airflow obstruction associated with chronic asthma and other chronic lung diseases (e.g., emphysema, chronic bronchitis),Adjunctive therapy in acute bronchial asthma and status asthmaticus,Off-label: Treatment of apnea of prematurity
400 mg intravenously once daily.
Loading dose: 5-6 mg/kg IV over 20-30 minutes (if not on theophylline). Maintenance: 0.5-0.7 mg/kg/h IV continuous infusion.
12-15 hours (terminal elimination half-life; allows once-daily dosing; may be prolonged in renal impairment).
Terminal elimination half-life: 3-12 hours in adults (mean 5-6 hours); prolonged in hepatic impairment, heart failure, COPD, and neonates (up to 30 hours). Smoking reduces half-life by 30-50%.
Moxifloxacin undergoes sulfate conjugation (phase II metabolism) via sulfotransferases; it is not metabolized by cytochrome P450 enzymes. Approximately 20% is excreted unchanged in urine, and 25% as a glucuronide conjugate.
Theophylline is metabolized primarily in the liver by cytochrome P450 isoenzymes, predominantly CYP1A2, with minor contributions from CYP2E1 and CYP3A4. Metabolism involves N-demethylation and oxidation. In neonates, metabolism is immature; in adults, ~90% is hepatically cleared. Ethylenediamine is minimally metabolized.
Renal (~20% unchanged, plus ~35% as glucuronide and sulfate conjugates), biliary/fecal (~25% unchanged and conjugates, total ~50% via feces).
Renal excretion of unchanged drug (about 10-20%) and metabolites (primarily 1,3-dimethyluric acid, 1-methyluric acid, 3-methylxanthine). Billary/fecal excretion is negligible.
~50% bound, primarily to serum albumin.
Theophylline (active moiety): approximately 40% bound to plasma proteins, primarily albumin. Protein binding decreases in neonates, hepatic cirrhosis, and uremia.
2.5–3.5 L/kg (indicates extensive tissue penetration, including lung and sinuses).
Apparent volume of distribution: approximately 0.4-0.6 L/kg (average 0.45 L/kg). Indicates distribution into total body water; slightly higher in neonates and premature infants.
Oral: ~90% (bioequivalent to IV).
Oral: 96-100% for immediate-release tablets; 50-70% for some sustained-release formulations depending on formulation. Rectal: 70-80% (variable). IV: 100%.
No dose adjustment required for GFR ≥30 m L/min; insufficient data for GFR <30 m L/min, use with caution.
No dose adjustment required for GFR >30 m L/min. For GFR 10-30 m L/min: reduce maintenance dose by 50% and monitor serum theophylline levels. For GFR <10 m L/min: reduce maintenance dose by 50% and extend dosing interval or use with caution.
No dose adjustment for Child-Pugh A or B; not recommended for Child-Pugh C due to lack of data.
Child-Pugh A: reduce dose by 50%. Child-Pugh B: reduce dose by 75%. Child-Pugh C: contraindicated or use with extreme caution, reduce dose by 80% and monitor levels.
Not recommended for patients <18 years due to risk of musculoskeletal adverse effects.
Loading dose: 1 mg/kg IV (if not on theophylline). Maintenance: Continuous infusion: age 6 months-1 year: 0.5 mg/kg/h; age 1-9 years: 0.8 mg/kg/h; age 9-12 years: 0.7 mg/kg/h; age 12-16 years: 0.6 mg/kg/h. Maximum daily dose: 24 mg/kg/day.
No specific dose adjustment; monitor for QT prolongation and tendon effects.
Consider lower initial doses due to decreased clearance. Use ideal body weight. Start at lower maintenance infusion rate (e.g., 0.3 mg/kg/h) and titrate based on serum levels and clinical response. Monitor for toxicity.
Fluoroquinolones, including moxifloxacin, are associated with an increased risk of tendinitis and tendon rupture in all ages. This risk is further increased in patients over 60 years of age, in those taking corticosteroids, and in kidney, heart, or lung transplant recipients. Fluoroquinolones may exacerbate muscle weakness in patients with myasthenia gravis. Avoid use in patients with known myasthenia gravis.
None
Tendon injury (tendinitis, tendon rupture),Worsening of myasthenia gravis,Peripheral neuropathy, irreversible,Central nervous system effects (seizures, dizziness, confusion),QT prolongation (avoid in patients with known QTc prolongation, electrolyte abnormalities, or concomitant QT-prolonging drugs),Hypersensitivity/anaphylactic reactions,Clostridioides difficile-associated diarrhea,Photosensitivity/phototoxicity,Blood glucose disturbances (especially in diabetic patients on oral hypoglycemics or insulin),Avoid in patients with known aortic aneurysm or at risk for aortic aneurysm
Narrow therapeutic index; serum theophylline levels must be monitored to avoid toxicity. Risk of seizures, cardiac arrhythmias, and death, especially at high serum concentrations. Caution in patients with hepatic impairment, congestive heart failure, cor pulmonale, fever, and in the elderly. Drug interactions with cimetidine, fluoroquinolones, macrolides, oral contraceptives, and other CYP1A2 inhibitors can increase toxicity.
Known hypersensitivity to moxifloxacin or any fluoroquinolone,Pregnancy (animal data showing fetal harm; avoid unless benefit outweighs risk),Lactation (not recommended; may cause articular damage in nursing infants),Patients under 18 years of age (except for specific approved indications like anthrax),History of tendon disorders related to fluoroquinolone use,Uncorrected hypokalemia or hypomagnesemia (risk of QTc prolongation),Concomitant use with Class IA or Class III antiarrhythmics (QT prolongation risk)
Absolute: Hypersensitivity to theophylline, ethylenediamine, or any component; use in patients with active seizure disorder (unless receiving appropriate anticonvulsant therapy); use in patients with a history of ventricular arrhythmias (except under close supervision). Relative: Peptic ulcer disease, hyperthyroidism, hypertension, and renal impairment.
Avoid concurrent intake of dairy products (milk, yogurt, cheese), antacids containing calcium, magnesium, or aluminum, and supplements with calcium, iron, or zinc. Separate dosing by at least 2 hours before or 6 hours after these products. Caffeine intake should be limited as moxifloxacin may increase its effects (nervousness, insomnia). No other significant food interactions.
Avoid large amounts of caffeine-containing foods and beverages (coffee, tea, cola, chocolate) as they can potentiate theophylline effects and increase risk of toxicity. A high-protein diet may increase theophylline clearance; maintain consistent dietary habits.
Moxifloxacin is contraindicated in pregnant women due to risk of fetal harm. Animal studies show arthropathy and cartilage damage in immature animals. Human data limited; avoid in all trimesters.
Pregnancy Category C. First trimester: Limited human data; animal studies show no teratogenicity but some developmental delays at high doses. Second and third trimesters: Use only if benefit outweighs risk; may cause fetal tachycardia or irritability due to adenosine receptor blockade. Avoid near term due to potential neonatal irritability.
Moxifloxacin is excreted in human milk; M/P ratio unknown. Potential for infant joint damage. Avoid breastfeeding or discontinue drug.
Not recommended unless essential. Aminophylline is excreted into breast milk; M/P ratio approximately 0.6–0.8. Monitor infant for irritability or insomnia. Consider alternative therapies if breastfeeding.
No dose adjustment established. Pregnancy is a contraindication; therefore, use only if no alternative and benefit outweighs risk. No pharmacokinetic studies in pregnancy.
Pregnancy may decrease protein binding and increase clearance of theophylline; monitor serum levels closely. Dose may need to be increased by 10–30% to maintain therapeutic levels. Postpartum, doses may need reduction.
Moxifloxacin is a fourth-generation fluoroquinolone with enhanced activity against Gram-positive bacteria and anaerobes. It achieves high tissue penetration, including into the CSF. Avoid in patients with known QT prolongation or uncorrected hypokalemia due to risk of torsades de pointes. Use with caution in elderly patients and those with renal impairment; no dose adjustment needed for renal impairment but adjust for hepatic impairment (Child-Pugh C). Monitor for signs of tendinitis or tendon rupture, especially in patients over 60, those on corticosteroids, or with kidney, heart, or lung transplants. Administer intravenous infusion over 60 minutes to reduce risk of infusion-related reactions.
Aminophylline is a bronchodilator used primarily for asthma and COPD exacerbations. Monitor serum theophylline levels closely due to narrow therapeutic index (10-20 mcg/m L). Administer IV infusion over 30 minutes to avoid hypotension. Caution in patients with cardiac arrhythmias, hyperthyroidism, or seizure disorders. Drug interactions include cimetidine, fluoroquinolones, and macrolides which increase theophylline levels.
Take this medication exactly as prescribed; do not skip doses or stop early even if you feel better.,Contact your doctor immediately if you experience tendon pain, swelling, or rupture (especially in the Achilles tendon), or if you have muscle weakness, joint pain, or difficulty moving.,Avoid excessive sunlight or UV light exposure; use sunscreen and protective clothing as this drug can cause photosensitivity.,This drug may cause dizziness or lightheadedness; do not drive or operate machinery until you know how it affects you.,Drink plenty of fluids to stay hydrated, unless instructed otherwise by your doctor.,Inform your doctor if you have a history of seizures, QT prolongation, heart rhythm problems, or if you are taking antiarrhythmics or other drugs that affect heart rhythm.,Do not take with dairy products, antacids, or supplements containing calcium, magnesium, aluminum, or iron; these can reduce drug absorption. Take moxifloxacin at least 2 hours before or 6 hours after these products.,Report any signs of allergic reaction: rash, hives, difficulty breathing, swelling of face, lips, or throat.
Take this medication exactly as prescribed; do not stop or change dose without consulting your doctor.,Avoid excessive caffeine intake (coffee, tea, chocolate, cola) as it may increase side effects like jitteriness and palpitations.,Report any symptoms of toxicity such as nausea, vomiting, insomnia, rapid heart rate, or seizures immediately.,Inform your healthcare provider of all other medications, especially antibiotics, heart medications, or seizure drugs.,Do not chew or crush the solution; it is for intravenous use only under medical supervision.
"Moxifloxacin, a fluoroquinolone antibiotic, and mefloquine, an antimalarial agent, both prolong the QT interval by inhibiting cardiac potassium channels (specifically hERG channels). When coadministered, there is an additive effect on QTc prolongation, increasing the risk of torsade de pointes and other ventricular arrhythmias. This interaction is particularly dangerous in patients with preexisting cardiac conditions, electrolyte imbalances, or bradycardia."
"Moxifloxacin, a fluoroquinolone antibiotic, can decrease the therapeutic efficacy of picosulfuric acid, a stimulant laxative used for bowel cleansing. This interaction likely occurs because moxifloxacin exhibits weak antagonistic activity at the 5-HT4 receptors in the gastrointestinal tract, partially counteracting the prokinetic and secretory effects mediated by picosulfuric acid. Consequently, patients may experience reduced bowel cleansing efficacy, potentially leading to inadequate colonic preparation for colonoscopy and increased risk of missed lesions."
"Dronedarone prolongs the QT interval by blocking multiple cardiac ion channels (primarily IKr). Moxifloxacin also prolongs the QT interval by blocking IKr. Coadministration leads to additive QTc prolongation, increasing the risk of torsades de pointes and ventricular arrhythmias. This risk is particularly elevated in patients with pre-existing electrolyte imbalances, bradycardia, or baseline QT prolongation."
"Concurrent administration of aminophylline, a xanthine derivative bronchodilator that is metabolized primarily by CYP1A2 and to a lesser extent CYP3A4, may reduce the clearance of ranolazine, an antianginal agent predominantly metabolized by CYP3A4 and to a lesser extent CYP2D6. Aminophylline can inhibit CYP3A4 activity, leading to increased ranolazine plasma concentrations, which elevates the risk of dose-dependent adverse effects such as QTc prolongation, dizziness, and syncope. This interaction is clinically significant and may necessitate dose adjustment or alternative therapy."
"Asunaprevir, a potent inhibitor of the drug transporter OATP1B1, can significantly decrease the serum concentration of aminophylline, a theophylline salt, likely by reducing its intestinal absorption or increasing its hepatic clearance. This interaction may lead to reduced therapeutic efficacy of aminophylline, potentially worsening respiratory symptoms in patients with asthma or COPD. Close monitoring and dose adjustment of aminophylline are recommended during coadministration with asunaprevir."
"Aminophylline, a bronchodilator, inhibits the metabolism of tibolone, a synthetic steroid hormone used for hormone replacement therapy, primarily through competitive inhibition of cytochrome P450 (CYP) 3A4 isoenzyme. This results in increased plasma concentrations of tibolone and its active metabolites, potentiating its hormonal effects and increasing the risk of adverse events such as thromboembolism, endometrial hyperplasia, or breast tenderness. Clinically, coadministration may require dose adjustments and careful monitoring for signs of estrogenic excess."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MOXIFLOXACIN HYDROCHLORIDE IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER vs AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, answered by our medical review team.
MOXIFLOXACIN HYDROCHLORIDE IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER is a Electrolyte that works by Inhibits DNA gyrase (topoisomerase II) and topoisomerase IV, thereby interfering with bacterial DNA replication, transcription, repair, and recombination.. AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER is a Electrolyte that works by Aminophylline is a complex of theophylline and ethylenediamine. Theophylline acts as a non-selective phosphodiesterase inhibitor, increasing intracellular cyclic AMP levels, leading to bronchodilation. It also blocks adenosine receptors, stimulates catecholamine release, and enhances diaphragmatic contractility. The ethylenediamine component increases solubility.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MOXIFLOXACIN HYDROCHLORIDE IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER and AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MOXIFLOXACIN HYDROCHLORIDE IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER is: 400 mg intravenously once daily.. The standard adult dose of AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER is: Loading dose: 5-6 mg/kg IV over 20-30 minutes (if not on theophylline). Maintenance: 0.5-0.7 mg/kg/h IV continuous infusion.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MOXIFLOXACIN HYDROCHLORIDE IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER and AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MOXIFLOXACIN HYDROCHLORIDE IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER is classified as Category A/B. Moxifloxacin is contraindicated in pregnant women due to risk of fetal harm. Animal studies show arthropathy and cartilage damage in immature animals. Human data limited; avoid in . AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER is classified as Category A/B. Pregnancy Category C. First trimester: Limited human data; animal studies show no teratogenicity but some developmental delays at high doses. Second and third trimesters: Use only . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.